Director Dealing

Crism Therapeutics Corporation
03 June 2024
 

3 June 2024

 

CRISM Therapeutics Corporation

(AIM:CRTX)

 

Director Dealing

 

CRISM Therapeutics Corporation ("CRISM" or the "Company") announces that it has been notified that Non-Executive Director, Gerald Beaney has purchased 25,000 ordinary shares of the Company at a price of 9.265 pence per share.

 

Following this purchase, Mr Beaney holds 25,000 ordinary shares, which represents approximately 0.08% of the Company's total issued share capital of 32,678,312.

 

 

Enquiries:

 

Company

Nomad and Broker

Financial PR

CRISM Therapeutics Corporation

S.P. Angel Corporate Finance LLP

Buchanan

Andrew Webb, CEO

Chris McConville, CSO

Richard Morrison

Adam Cowl

 

Mark Court mark.court@buchanancomms.co.uk

Jamie Hooper jamie.hooper@buchanancomms.co.uk

via Buchanan

+44 (0) 20 3470 0470

+44 (0) 20 7466 5000

 

 

 

Dealings by Persons Discharging Managerial Responsibilities

 

 1

 

Details of the person discharging managerial responsibilities / person closely associated

 

a)

 

Name

Gerald Beaney

2

 

Reason for the notification

 

a)

 

Position/status

Non-Executive Director

b)

 

Initial notification /Amendment

 Initial Notification

3

 

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

 

Name

 CRISM Therapeutics Corporation

b)

 

LEI

 

213800XFW6MKVCHHPW88

 

 

4

 

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

a)

 

Description of the financial instrument, type of instrument

Ordinary shares with no par value



Identification code

ISIN: VGG042401262

 



b)

 

Nature of the transaction

 

Purchase of shares

c)

 

Price(s) and volume(s)

 

 

 

 

Director/PDMR

Price

Volume

Gerald Beaney

9.265

25,000

 

 

 

 

 

 

 

 

 

 

 

d)

 

Aggregated information




- Aggregated volume

 25,000



- Price

£2,316.25



e)

 

Date of the transaction

3 June 2024

f)

 

Place of the transaction

Outside a trading venue

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
UK 100

Latest directors dealings